Preparation is Key to Tackle the Transition from Fellow to Attending Physician
A lymphoma hematologist/oncologist who recently transitioned from a fellow to an attending physician shares his experience with the change and tips for fellows.
Related Articles
Ide-Cel Shows Real-World Efficacy in CNS Multiple Myeloma
Real-world data showed ide-cel was active in patients with central nervous system manifestations of multiple myeloma.
CD37 in acute myeloid leukemia: a novel surface target for drug delivery
Key PointsCD37 is a surface receptor present on most AML blasts, which has unique internalization properties when compared with normal blood cells.Treatmen
Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma
PURPOSEDenileukin diftitox (DD)-cxdl is a fusion protein comprising diphtheria toxin fragments A and B and human interleukin-2. This phase III, multicenter, open-label, single-arm registrational trial…
Iopofosine I 131 Is Efficacious, Tolerable in Heavily Pretreated R/R Waldenström Macroglobulinemia
Iopofosine I 131 demonstrated durable efficacy and tolerability in heavily pretreated relapsed/refractory Waldenström macroglobulinemia.
Momelotinib Shows Real-World Improvements in Anemia, Symptoms, and Spleen Response in Myelofibrosis
Real-world treatment with momelotinib led to high transfusion independence rates among patients with JAK inhibitor–exposed and –naive myelofibrosis.
Risk Management Measures Improved Safety, Prevention, and Management of Ponatinib-Associated AEs in CML and AML
Select safety measures have improved the prevention and management of risks associated with ponatinib in ALL and CML over 10 years.
Advancing Trials for HER2+ Breast Cancer With Leptomeningeal Metastasis
Barbara O’Brien, MD, discusses the next steps of the phase 2 TBCRC049 study for the treatment of patients with HER2-positive breast cancer and leptomeningeal metastasis.
Employee Recognition Has Fox Chase Seeing STARs
On Thursday, November 14, 2024, Fox Chase Cancer Center announced the inaugural cohort of STAR Award winners. STAR – Special Talent Achieving Results – is…
Understanding When to Choose Systemic Treatment for Desmoid Tumors
Mark Agulnik, MD, discusses the intricacies of desmoid tumors that can be recognized before starting treatment for patients.
118 COOs to know | 2024
Becker’s is thrilled to spotlight 118 outstanding hospital and health system chief operating officers.
